1. Moderna said March 8 that it partnered with Baxter International to boost its supply of COVID-19 vaccines by 60 million to 90 million doses this year.
2. Moderna said March 10 it began the first human trial of a modified version of its COVID-19 vaccine designed to combat the virus variant first found in South Africa, called B.1.351.
3. Sanofi began a phase 1/2 human trial for the mRNA COVID-19 vaccine candidate it is developing with Lexington, Mass.-based mRNA therapeutics company Translate Bio.
4. The U.S. has given more than 100 million COVID-19 vaccine doses as of March 12, according to data from the CDC.
5. Japanese drugmaker Takeda signed an agreement March 15 to use contract development and manufacturing company IDT Biologika’s facility, which was previously reserved for Takeda’s dengue vaccine candidate, to manufacture Johnson & Johnson’s COVID-19 vaccine.
More articles on surgery centers:
4 new joint-venture ASCs | February 2021
Dr. Barbara Bergin’s outlook on orthopedics in ASCs
UC Davis Health building medical campus with ASC
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.